Pharmaceuticals, Biotechnology and Life Sciences
LEO Pharma UK said that the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission (EC) has approved tralokinumab for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
On Tuesday, Novartis disclosed new data showing mean IgG and IgM levels remain unchanged in adults with relapsing multiple sclerosis (RMS) treated with Kesimpta® (ofatumumab) over 3.5 years.
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for investigational, long-acting, injectable cabotegravir for the prevention of HIV, also called pre-exposure prophylaxis, or PrEP.
Bora Pharmaceutical Services Inc., a division of Bora Pharmaceuticals, has announced that its Mississauga, Ontario contract manufacturing and packaging facility has successfully completed its first Health Canada inspection since being aquired by the company.
A certain peer-reviewed study (see more here) carried out at the Welcare Hospital, India, found out that kitchen staple, bicarbonate of soda is found to significantly reduce Covid-19 symptoms.
AstraZeneca has issued a statement to clarify a number of inaccurate statements relating to COVID-19 Vaccine AstraZeneca doses at the Anagni plant in Italy.
AstraZeneca’s AZD1222 got positive high-level results from the primary analysis of the Phase III trial which in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021.
Novadiscovery has entered into a new collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) aimed at incorporating clinical simulation technology on virtual patients into Takeda France’s access strategy.
Novo Nordisk’a new results from the STEP phase 3a clinical trial programme showed weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.
Bayer has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi, for the treatment of Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion-positive advanced or recurrent solid tumors.